Risk factors for pediatric surgical site infection following neurosurgical procedures for hydrocephalus: a retrospective single-center cohort study.
Adolescent
Anti-Bacterial Agents
/ administration & dosage
Antibiotic Prophylaxis
/ adverse effects
Cardiovascular Diseases
/ complications
Child
Child, Preschool
Clindamycin
/ administration & dosage
Cohort Studies
Female
Humans
Hydrocephalus
/ surgery
Infant
Infant, Newborn
Male
Neurosurgical Procedures
Retrospective Studies
Risk Factors
Surgical Wound Infection
/ epidemiology
Hydrocephalus
SSI
Shunt
Surgical site infections
Journal
BMC anesthesiology
ISSN: 1471-2253
Titre abrégé: BMC Anesthesiol
Pays: England
ID NLM: 100968535
Informations de publication
Date de publication:
21 04 2021
21 04 2021
Historique:
received:
12
01
2021
accepted:
12
04
2021
entrez:
22
4
2021
pubmed:
23
4
2021
medline:
6
1
2022
Statut:
epublish
Résumé
Infection is a major complication following cerebral spinal fluid (CSF) diversion procedures for hydrocephalus. However, pediatric risk factors for surgical site infection (SSI) are currently not well defined. Because a SSI prevention bundle is increasingly introduced, the purpose of this study was to evaluate risk factors associated with SSIs following CSF diversion surgeries following a SSI bundle at a single quaternary care pediatric hospital. We performed a retrospective cohort study of patients undergoing CSF diversion procedures from 2017 to 2019. SSIs were identified prospectively through continuous surveillance. We performed unadjusted logistic regression analyses and univariate analyses to determine an association between SSIs and patient demographics, comorbidities and perioperative factors to identify independent risk factors for SSI. We identified a total of 558 CSF diversion procedures with an overall SSI rate of 3.4%. The SSI rates for shunt, external ventricular drain (EVD) placement, and endoscopic third ventriculostomy (ETV) were 4.3, 6.9 and 0%, respectively. Among 323 shunt operations, receipt of clindamycin as perioperative prophylaxis and presence of cardiac disease were significantly associated with SSI (O.R. 4.99, 95% C.I. 1.27-19.70, p = 0.02 for the former, and O.R. 7.19, 95% C.I. 1.35-38.35, p = 0.02 for the latter). No risk factors for SSI were identified among 72 EVD procedures. We identified receipt of clindamycin as perioperative prophylaxis and the presence of cardiac disease as risk factors for SSI in shunt procedures. Cefazolin is recommended as a standard antibiotic for perioperative prophylaxis. Knowing that unsubstantiated beta-lactam allergy label is a significant medical problem, efforts should be made to clarify beta-lactam allergy status to maximize the number of patients who can receive cefazolin for prophylaxis before shunt placement. Further research is needed to elucidate the mechanism by which cardiac disease may increase SSI risk after shunt procedures.
Sections du résumé
BACKGROUND
Infection is a major complication following cerebral spinal fluid (CSF) diversion procedures for hydrocephalus. However, pediatric risk factors for surgical site infection (SSI) are currently not well defined. Because a SSI prevention bundle is increasingly introduced, the purpose of this study was to evaluate risk factors associated with SSIs following CSF diversion surgeries following a SSI bundle at a single quaternary care pediatric hospital.
METHODS
We performed a retrospective cohort study of patients undergoing CSF diversion procedures from 2017 to 2019. SSIs were identified prospectively through continuous surveillance. We performed unadjusted logistic regression analyses and univariate analyses to determine an association between SSIs and patient demographics, comorbidities and perioperative factors to identify independent risk factors for SSI.
RESULTS
We identified a total of 558 CSF diversion procedures with an overall SSI rate of 3.4%. The SSI rates for shunt, external ventricular drain (EVD) placement, and endoscopic third ventriculostomy (ETV) were 4.3, 6.9 and 0%, respectively. Among 323 shunt operations, receipt of clindamycin as perioperative prophylaxis and presence of cardiac disease were significantly associated with SSI (O.R. 4.99, 95% C.I. 1.27-19.70, p = 0.02 for the former, and O.R. 7.19, 95% C.I. 1.35-38.35, p = 0.02 for the latter). No risk factors for SSI were identified among 72 EVD procedures.
CONCLUSION
We identified receipt of clindamycin as perioperative prophylaxis and the presence of cardiac disease as risk factors for SSI in shunt procedures. Cefazolin is recommended as a standard antibiotic for perioperative prophylaxis. Knowing that unsubstantiated beta-lactam allergy label is a significant medical problem, efforts should be made to clarify beta-lactam allergy status to maximize the number of patients who can receive cefazolin for prophylaxis before shunt placement. Further research is needed to elucidate the mechanism by which cardiac disease may increase SSI risk after shunt procedures.
Identifiants
pubmed: 33882858
doi: 10.1186/s12871-021-01342-5
pii: 10.1186/s12871-021-01342-5
pmc: PMC8059169
doi:
Substances chimiques
Anti-Bacterial Agents
0
Clindamycin
3U02EL437C
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
124Subventions
Organisme : NIGMS NIH HHS
ID : R01 GM127600
Pays : United States
Références
Clin Microbiol Infect. 2000 Apr;6(4):202-6
pubmed: 11168108
Cardiovasc Hematol Disord Drug Targets. 2015;15(1):57-69
pubmed: 25567335
Infection. 1993 Mar-Apr;21(2):89-92
pubmed: 8491526
Eur J Paediatr Neurol. 2020 May;26:7-14
pubmed: 32139243
J Neurosurg. 2015 Feb;122(2):443-8
pubmed: 25415066
J Anesth. 2011 Apr;25(2):247-56
pubmed: 21197552
J Neurosurg Pediatr. 2015 Feb;15(2):156-60
pubmed: 25479576
Acta Neurochir (Wien). 1996;138(7):829-34
pubmed: 8869711
Anesth Analg. 2013 Oct;117(4):803-11
pubmed: 23960033
Pediatr Neurosurg. 1993 Sep-Oct;19(5):233-41; discussion 242
pubmed: 8398847
Am J Infect Control. 1999 Apr;27(2):97-132; quiz 133-4; discussion 96
pubmed: 10196487
Korean J Anesthesiol. 2016 Aug;69(4):332-40
pubmed: 27482309
Toxicol Sci. 2017 Apr 1;156(2):402-411
pubmed: 28003439
J Neurosurg Pediatr. 2011 Jul;8(1):22-9
pubmed: 21721884
Pediatr Neurosurg. 2003 Jun;38(6):295-301
pubmed: 12759508
N Engl J Med. 2000 Jan 20;342(3):161-7
pubmed: 10639541
Anesth Analg. 2016 Aug;123(2):326-35
pubmed: 27308954
J Anesth. 2013 Apr;27(2):261-8
pubmed: 23096126
Pediatr Neurosurg. 1999 May;30(5):253-7
pubmed: 10461072
FASEB J. 2012 Nov;26(11):4408-17
pubmed: 22815384
J Neurosurg Pediatr. 2009 Aug;4(2):156-65
pubmed: 19645551
Br J Anaesth. 2019 Jul;123(1):e82-e94
pubmed: 30916014
J Neurosurg Pediatr. 2016 Apr;17(4):382-90
pubmed: 26636251
Lancet. 2016 Feb 20;387(10020):788-99
pubmed: 26256071
Toxicol Lett. 2017 Jan 15;266:23-31
pubmed: 27940100
Am J Obstet Gynecol MFM. 2020 Feb;2(1):100074
pubmed: 33345988
PLoS One. 2013;8(4):e60415
pubmed: 23573252
J Thorac Cardiovasc Surg. 2013 Mar;145(3):656-62, 662.e1-2; discussion 662
pubmed: 23312343
J Pediatr. 2014 Jun;164(6):1462-8.e2
pubmed: 24661340
J Neurosurg. 2000 Jan;92(1):31-8
pubmed: 10616079
J Pediatric Infect Dis Soc. 2019 Jul 1;8(3):235-243
pubmed: 29771360
Best Pract Res Clin Anaesthesiol. 2015 Jun;29(2):241-56
pubmed: 26060033
Lancet. 2001 Sep 15;358(9285):876-80
pubmed: 11567703
Acta Paediatr. 1998 Jun;87(6):667-70
pubmed: 9686660
Neurosurg Focus. 2007 Apr 15;22(4):E9
pubmed: 17613199
J Neurosurg Pediatr. 2013 Jul;12(1):44-8
pubmed: 23682818
J Neurosurg Pediatr. 2014 Nov;14 Suppl 1:53-9
pubmed: 25988783
J Neurosurg. 2015 Dec;123(6):1447-55
pubmed: 26207604
J Surg Res. 2021 Mar;259:546-554
pubmed: 33223141
J Neurosurg Pediatr. 2012 Jan;9(1):54-63
pubmed: 22208322
Lancet. 2019 Oct 26;394(10208):1530-1539
pubmed: 31522843
J Neurosurg. 2015 May;122(5):1096-112
pubmed: 25768831
Anesth Analg. 2011 Apr;112(4):830-8
pubmed: 21385989
J Neurosurg Pediatr. 2008 Feb;1(2):131-7
pubmed: 18352782
Childs Brain. 1984;11(2):112-8
pubmed: 6723425
J Clin Neurosci. 2005 Feb;12(2):147-9
pubmed: 15749415
J Neurosurg Pediatr. 2014 Nov;14 Suppl 1:44-52
pubmed: 25988782
J Neurosurg. 1992 Jul;77(1):29-36
pubmed: 1607969
Acta Neurochir (Wien). 2013 Mar;155(3):523-31
pubmed: 23224578